Takeda Pharmaceutical Co. Ltd. purchased a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 823,317 shares of the company's stock, valued at approximately $527,000. Lyell Immunopharma comprises 2.0% of Takeda Pharmaceutical Co. Ltd.'s holdings, making the stock its 7th biggest holding. Takeda Pharmaceutical Co. Ltd. owned about 0.28% of Lyell Immunopharma at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in LYEL. JPMorgan Chase & Co. increased its stake in shares of Lyell Immunopharma by 347.8% in the 4th quarter. JPMorgan Chase & Co. now owns 433,265 shares of the company's stock valued at $277,000 after buying an additional 336,516 shares during the period. Charles Schwab Investment Management Inc. increased its position in Lyell Immunopharma by 43.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,645,787 shares of the company's stock worth $1,053,000 after purchasing an additional 498,417 shares during the period. SG Americas Securities LLC increased its position in Lyell Immunopharma by 102.8% in the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock worth $75,000 after purchasing an additional 59,182 shares during the period. Barclays PLC raised its holdings in Lyell Immunopharma by 312.7% during the 3rd quarter. Barclays PLC now owns 240,615 shares of the company's stock worth $332,000 after purchasing an additional 182,315 shares during the last quarter. Finally, Jane Street Group LLC lifted its position in Lyell Immunopharma by 63.7% during the 3rd quarter. Jane Street Group LLC now owns 287,717 shares of the company's stock valued at $397,000 after purchasing an additional 111,917 shares during the period. Institutional investors and hedge funds own 66.05% of the company's stock.
Insider Buying and Selling
In other Lyell Immunopharma news, Director Richard Klausner acquired 158,000 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average price of $0.60 per share, with a total value of $94,800.00. Following the purchase, the director now owns 843,365 shares of the company's stock, valued at $506,019. This represents a 23.05 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Lynn Seely bought 175,000 shares of the firm's stock in a transaction on Friday, March 14th. The stock was acquired at an average cost of $0.61 per share, with a total value of $106,750.00. Following the completion of the purchase, the chief executive officer now owns 712,500 shares of the company's stock, valued at approximately $434,625. This trade represents a 32.56 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 733,000 shares of company stock valued at $429,550 in the last 90 days. 25.10% of the stock is owned by insiders.
Lyell Immunopharma Trading Down 4.1 %
Shares of NASDAQ:LYEL traded down $0.02 during midday trading on Monday, hitting $0.52. The company had a trading volume of 236,825 shares, compared to its average volume of 1,021,755. Lyell Immunopharma, Inc. has a 12 month low of $0.48 and a 12 month high of $3.15. The firm has a fifty day simple moving average of $0.61 and a 200 day simple moving average of $0.86. The stock has a market cap of $153.22 million, a price-to-earnings ratio of -0.66 and a beta of -0.41.
Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. Equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a "neutral" rating and set a $1.00 price target on shares of Lyell Immunopharma in a research report on Thursday, March 13th.
Get Our Latest Research Report on LYEL
Lyell Immunopharma Profile
(
Free Report)
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
See Also
Before you consider Lyell Immunopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.
While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
